Physician profile
Stefanie M Jackson
NPI 1346204427
$4,234.60
in general payments reported to CMS, 2019-2025
34 companies · $712 in 2025
The $712 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,002 · 2022: $857 · 2023: $869 · 2024: $795 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,375.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,319.60 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $326.33 | 2021-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $278.05 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $275.14 | 2021-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $255.95 | 2021-2025 | |
| Lilly USA, LLC | $233.17 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $166.02 | 2021-2024 | Verquvo, Dificid |
| Bayer Healthcare Pharmaceuticals INC. | $137.99 | 2021-2025 | |
| Abbvie INC. | $136.33 | 2021-2025 | |
| Exact Sciences Corporation | $131.45 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $130.86 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Mylan Specialty L.P. | $98.40 | 2021-2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $86.32 | 2021 | |
| Edwards Lifesciences Corporation | $71.72 | 2023-2024 | Sapien 3 Ultra Resilia |
| Esperion Therapeutics, INC. | $67.85 | 2021-2024 | Nexletol |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $58.49 | 2021-2022 | |
| Biogen, INC. | $51.28 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.99 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $43.78 | 2024 | Voquezna |
| Astellas Pharma US INC | $39.72 | 2023-2025 | Veozah |
| Biohaven Pharmaceuticals, INC. | $31.63 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $26.72 | 2022-2024 | Airsupra |
| Becton, Dickinson and Company | $26.59 | 2022 | |
| Lundbeck LLC | $24.20 | 2024 | Vyepti |
| Nestle Healthcare Nutrition INC. | $20.84 | 2023 | |
| Inspire Medical Systems, INC. | $20.76 | 2023 | Inspire |
| Boston Scientific Corporation | $19.55 | 2024 | Watchman Flx |
| Sanofi Pasteur INC. | $17.17 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.49 | 2022 | |
| Currax Pharmaceuticals LLC | $16.26 | 2023 | Contrave |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.72 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.93 | 2023 | Trulance, Xifaxan |
| Dexcom, INC. | $13.44 | 2023 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $12.86 | 2023 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefanie Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.